Epigenic Therapeutics Announced to be listed in“Forbes Asia 100 To Watch 2024”
Shanghai, China, 29 August 2024—Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, officially announced to be listed in “Forbes Asia 100 To Watch 2024”.
The fourth annual Forbes Asia 100 to Watch list showcases small companies and startups in Asia-Pacific that grabbed investors’ attention—and their checkbooks. These 100 companies demonstrate strong innovation capabilities.” Their offerings range from AI navigation systems for space exploration to cutting-edge cell therapies to advanced healthcare diagnostics. Companies from 16 countries and territories are represented on this year’s list, operating in a total of 10 industries, such as enterprise technology and robotics, finance, and manufacturing and energy. India has the biggest presence this year with 20 companies, followed by Singapore (15), mainland China (10), Japan (9) and Indonesia (8). With the outstanding innovation capabilities and leading technology, Epigenic Therapeutics stood out among many companies and successfully be listed in “Forbes Asia 100 To Watch 2024”.
In the future，our company will continue to deepen research in the life sciences field，consistently strengthen the innovative capabilities and strive to provide safer and more effective treatment options for chronic disease patients. Our goal is to maintain the leading position of the epigenetic therapy, take more treatment options to patients worldwide and promote the widespread application of gene regulation therapies.
About Epigenic Therapeutics
Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene modulation therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene modulation technologies and developing gene modulation therapies, the company has multiple product candidates in the pipeline, including treatment for ocular, neurodegeneration, metabolic, and rare diseases. For more information, visit www.epigenictx.com
Contact
